8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Nov 15, 2024)

Filed November 15, 2024For Securities:BSX

Summary

Boston Scientific Corporation (BSX) has announced the completion of its acquisition of Axonics, Inc., a medical technology company specializing in urinary and bowel dysfunction devices. The deal was finalized on November 15, 2024, for $71 in cash per share, representing an equity value of $3.7 billion and an enterprise value of $3.3 billion after accounting for acquired cash and investments. This strategic acquisition is expected to have a minimal impact on adjusted earnings per share (EPS) in 2024 and 2025, becoming accretive thereafter. On a GAAP basis, the transaction is anticipated to be less accretive or more dilutive due to amortization expenses and acquisition-related costs. Investors should note the forward-looking statements and the cautionary notes regarding potential risks and uncertainties that could affect actual results.

Key Highlights

  • 1Boston Scientific has successfully acquired Axonics, Inc. for $71 per share in cash.
  • 2The total equity value of the transaction is $3.7 billion, with an enterprise value of $3.3 billion.
  • 3Axonics is a developer of medical devices for urinary and bowel dysfunction.
  • 4The acquisition is expected to be immaterial to adjusted EPS in 2024 and 2025, becoming accretive thereafter.
  • 5GAAP EPS is expected to be less accretive or more dilutive due to amortization and acquisition-related charges.
  • 6The transaction is officially closed as of November 15, 2024.

Frequently Asked Questions

Axonics focuses on differentiated devices to treat urinary and bowel dysfunction. Boston Scientific likely sees this as an opportunity to expand its portfolio in a specialized medical technology area with potential for growth and synergistic benefits.

The acquisition is expected to have a negligible impact on adjusted earnings per share (EPS) in 2024 and 2025, with accretion anticipated in subsequent years. However, on a GAAP basis, the transaction may result in less accretion or dilution due to amortization expenses and acquisition-related costs.

The acquisition was completed at a price of $71 cash per share. This represents an equity value of $3.7 billion and an enterprise value of $3.3 billion, after deducting the cash and short-term investments acquired from Axonics.

The filing includes standard cautionary statements about forward-looking statements. Potential risks that could impact the actual results of the acquisition include integration challenges, competitive pressures, reimbursement changes, regulatory conditions, and unforeseen economic or geopolitical factors, among others. Investors are advised to review the company's most recent SEC filings for a comprehensive list of risk factors.